What changed · written from our data
As of Nov 12, 2026Mentari Therapeutics closed at $18.35 on Nov 12, up 17.56% — matching its highest close since Nov 9.
Short interest was 8.3K shares at the Sep 15 settlement (0.2% of float, 1.0 days to cover).
Mentari Therapeutics, Inc. Common Stock (MTRI)
$18.35+17.56%
Close Nov 12, 2026 · split-adjustedNov 12, 2026$18.35▲ 14.69% in range
Nov 9, 2026Low $12.20 · High $18.35Nov 12, 2026
Market cap$1.07B58.3M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Nov 912.20 – 18.350.0% from high
Volume145.6K
Volatility · 60d—Annualised
Short % of float0.2%1.0 days to cover
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W —1M —3M —6M —YTD —1Y —3Y —5Y —Earnings reactions
History →No reported quarters with price history yet.
Rank within Pharmaceuticals
Percentile among 417 companies (100 = best)
6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size71
Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.
Short interest
Details →Shares short8.3K0.0% vs prior
Days to cover1.0Settled Sep 15
% of float0.2%
Short vol. 10d22.6%of daily volume
Closest peers by size in Pharmaceuticals
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MTRIMentari Therapeutics | $18.35 | +17.56% | — | — | — | — | $1.07B | |
| VSTMVerastem | $8.44 | −7.15% | +79.2% | +113.6% | −311.2% | — | $1.06B | Compare |
| HROWHarrow | $28.30 | −3.64% | −8.3% | +38.6% | 9.8% | — | $1.06B | Compare |
| SPTXSeaport Therapeutics | $20.13 | −5.54% | — | — | — | — | $1.08B | Compare |
| MLTXMoonLake Immunotherapeutics | $12.87 | −4.74% | −30.0% | — | — | — | $1.10B | Compare |
| SVRASavara | $4.72 | −5.41% | −10.4% | — | — | — | $1.04B | Compare |
| CYRXCryoPort | $20.10 | −2.24% | +51.9% | +13.5% | −25.6% | — | $1.02B | Compare |
| JBIOJade Biosciences | $15.87 | −4.05% | −34.2% | — | — | — | $1.01B | Compare |
| MRVIMaravai LifeSciences Holdings | $7.68 | −0.26% | +79.0% | +10.1% | −30.2% | — | $1.15B | Compare |
News about Mentari Therapeutics
All news →No recent articles focused on Mentari Therapeutics.
Quick answers
- What does Mentari Therapeutics do?
- Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways.
- What is MTRI's market cap?
- $1.07B, based on the Nov 12 close of $18.35.
- How much of MTRI is sold short?
- 8.3K shares, 0.2% of float, as of Sep 15, 2022.
- What sector is MTRI in?
- Healthcare, in the Pharmaceuticals industry.
About Mentari Therapeutics
Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology